Newron Pharmaceuticals Seeks FDA Resolution on Evenamide Trial Hold — Newron Pharmaceuticals S.p.A.

Event summary

Newron Pharmaceuticals held a Type A meeting with the FDA on July 2, 2026, to address the enrollment hold in its Phase III ENIGMA-TRS 2 study of evenamide for treatment-resistant schizophrenia (TRS).
The FDA and Newron discussed potential actions to resolve issues that led to the clinical hold.
ENIGMA-TRS 1 is ongoing with 600+ patients across Europe, Asia, Latin America, and Canada, while ENIGMA-TRS 2 aims to enroll at least 400 patients in the U.S. and other selected countries.

The big picture

Newron Pharmaceuticals is navigating a critical regulatory hurdle with its Phase III trial of evenamide, a first-in-class glutamate modulator for treatment-resistant schizophrenia. The outcome of this FDA meeting will be pivotal in determining the future trajectory of the drug’s development and commercialization potential. With existing partnerships in key markets like Japan and South Korea, resolving this clinical hold is essential for maintaining momentum in Newron's pipeline.

What we're watching

Regulatory Resolution: The pace at which Newron and the FDA reach an agreement will determine the timeline for resuming ENIGMA-TRS 2 enrollment in the U.S.
Trial Execution: Whether Newron can successfully address the FDA’s concerns and propose changes that satisfy regulatory requirements.
Market Impact: How delays in the ENIGMA-TRS 2 study could affect investor confidence and potential partnerships for evenamide.